Loading...
•
Dec 31, 2021
Editas Q4 2021 Earnings Report
Editas Medicine reported a net loss and increased collaboration revenue for Q4 2021.
Key Takeaways
Editas Medicine reported a net loss of $41.4 million for the fourth quarter of 2021, with collaboration and other research and development revenues increasing to $12.5 million. The company's cash, cash equivalents, and marketable securities totaled $619.9 million as of December 31, 2021, expected to fund operations through 2023.
EDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H 2022
EDIT-301 remains on track to dose first sickle cell disease patient in 1H 2022 and first TDT patient in 2022
EDIT-103 for RHO-adRP and EDIT-202 for solid tumors advancing towards IND-enabling studies
First ever in vivo ocular gene editing data demonstrated evidence of gene editing and potential clinical benefit; clinical update expected in 2H 2022
Forward Guidance
Editas Medicine anticipates several milestones in 2022, including clinical data updates for EDIT-101 and EDIT-301, the start of patient dosing in the beta thalassemia trial, and the beginning of IND-enabling studies for EDIT-202.
Positive Outlook
- Completing dosing of the pediatric mid-dose cohort in the first half of 2022
- Initiating dosing of the pediatric high-dose cohort in the BRILLIANCE trial in 2022
- Establishing registrational trial criteria by year-end 2022
- Dosing the first patient in the RUBY trial in the first half of 2022
- Dosing the first TDT patient with EDIT-301 in 2022
Challenges Ahead
- Uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials
- Availability and timing of results from pre-clinical studies and clinical trials
- Whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...